WorldCat Identities

Sautenet, Bénédicte (1983-....).

Works: 13 works in 14 publications in 2 languages and 19 library holdings
Roles: Other, Opponent, Author
Publication Timeline
Most widely held works by Bénédicte Sautenet
Traitement d'induction chez le patient transplanté rénal immunisé sans DSA pré-greffe by Annabelle Goumard( )

2 editions published in 2018 in French and held by 3 WorldCat member libraries worldwide

Background. Basiliximab induction was reserved to unimmunized patients. However, the improvement of immunological risk determination led to its utilisation for immunised patients without donor specific antibodies (DSA). The objective was to study the efficiency of basiliximab in immunized kidney transplanted recipients (KTR) without DSA. Methods. Monocentric retrospective study included all adults renal transplant recipient since single antigen bead (SAB) assay introduction in 2007 June until 2017 June. DSA absence detected by SAB has been validated after each folder analysis. Univariate and multivariate analysis of biopsy proven acute rejection (BPAR) risk and DSA appearance has been done. Results. 218 (21%) immunized kidney transplant recipients without pre-graft DSA were identified (basiliximab=60; rATG=158). Patients treated with basiliximab had a lower cPRA (24±26 vs, 66±32, p <0.0001), were more likely to receive a first graft (88 vs 63%, p <0,0001) or a transplant with a living donor (13% vs 2%, p= 0.005). During the mean follow up of 4 years, BPAR risk was higher in basiliximab group (n=15, 25%) than in rATG group (n=13, 8.2%) (p=0.0009). This increased risk remained after adjustment for models different. The occurrence of DSA (MFI> 1000) was observed in 13 (21.7%) and 25 (15.8%) patients treated with basiliximab and rATG respectively (p = 0.167). Moreover, no difference side effects have been noticed between the 2 groups. Conclusions. These results suggest that the use of rATG should be preferable in the prevention of BPAR in immunized KTR without pre-grafts DSA
Prise en compte de l'insuffisance rénale dans les comptes-rendus d'hospitalisation du CHRU de Tours du 1er novembe 2008 au 30 avril 2009 by Bénédicte Sautenet( Book )

1 edition published in 2012 in French and held by 2 WorldCat member libraries worldwide

Le compte-rendu d'hospitalisation (CR11) est le document clé de la transmission d'informations entre l'hôpital et la ville. Le dosage de la créatinine plasmatique est effectué chez la plupart des patients hospitalisés, ce qui permet d'identifier l'existence d'une insuffisance rénale (IR). Cette R doit être connue des médecins car elle nécessite un recours précoce au néphrologue et joue un rôle pronostique cardiovasculaire, rénal et vital majeur. Cependant, les données de la littérature ne permettent pas de savoir comment l'existence d'une IF. à l'hôpital est transmise aux médecins de ville. Dans cette étude, nous avons analysé la fréquence de l'IF. dans un CHRU, si elle était notifiée dans les CR11, et la façon dont elle l'était. Méthodes: Dans cette étude rétrospective, nous avons collecté tous les dosages de créatinine plasmatique réalisés du l novembre 2008 au 30 avril 2009 au CHRU de Tours, et estimé le débit de filtration gloménilafre (DFG) correspondant par la formule simplifiée de MDRD. Les séjours de 11 unités médicales, il unités chirurgicales et 4 unités de soins intensifs (USI) au cours desquels au moins un DFG < 6OmlImi&l .73m2 (définissant l'IF.) était constaté ont été analysés par un néphrologue. Les CR11 correspondants contenant un mot-clé évocateur d'une atteinte néphrologique ont tous été relus par un néphrologue. Résultats: Une IR était observée dans 28.0% des 14 616 séjours analysés et cette 1F. était persistante à la sortie du patient dans 61.2% des cas. L'IF. était signalée dans 26.1% des CR11 (36.3% lorsque l'IF. était persistante) et cette notification restait faible quels que soient les services considérés (USL 48.4%; unités chirurgicales: 16.3%; unités médicales: 25.0%). Cette notification était présente dans la conclusion de seulement 11.8% des CRH (16.4% lorsque l'IF. était persistante). L'existence d'une R était notifiée dans 16.9%, 65.6% et 83.0% lorsque le DFG était compris entre 30 et 59, 15 et 29, et O et 14 mllmin/1.73m2 respectivement. Un avis néphrologique durant l'hospitalisation et/ou une consultation de néphrologie ultérieure étaient indiqués dans 6.7% des CR11. Conclusion: L'IF. s'avère fréquente chez les patients hospitalisés, mais est peu notifiée dans les CR11, quel que soit le type d'unité considérée, même lorsque l'IF. est persistante à la sortie du patient. L'IF. est donc peu transmise aux médecins de ville. Cet élément joue probablement un rôle important dans le retard au recours à l'avis néphrologique
Forensic age estimation using computed tomography of the medial clavicular epiphysis: a systematic review by Coralie Hermetet( )

1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide

Standardised Outcomes in Nephrology--Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease by Yeoungjee Cho( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

Arginine Vasopressin and Posterior Reversible Encephalopathy Syndrome Pathophysiology: the Missing Link? by Bérenger Largeau( )

1 edition published in 2019 in English and held by 2 WorldCat member libraries worldwide

Developing Consensus-Based Priority Outcome Domains for Trials in Kidney Transplantation( )

1 edition published in 2017 in English and held by 1 WorldCat member library worldwide

Abstract : Background: Inconsistencies in outcome reporting and frequent omission of patient-centered outcomes can diminish the value of trials in treatment decision making. We identified critically important outcome domains in kidney transplantation based on the shared priorities of patients/caregivers and health professionals. Methods: In a 3-round Delphi survey, patients/caregivers and health professionals rated the importance of outcome domains for trials in kidney transplantation on a 9-point Likert scale and provided comments. During rounds 2 and 3, participants rerated the outcomes after reviewing their own score, the distribution of the respondents' scores, and comments. We calculated the median, mean, and proportion rating 7 to 9 (critically important), and analyzed comments thematically. Results: One thousand eighteen participants (461 [45%] patients/caregivers and 557 [55%] health professionals) from 79 countries completed round 1, and 779 (77%) completed round 3. The top 8 outcomes that met the consensus criteria in round 3 (mean, e".5; median, e"; proportion,>85%) in both groups were graft loss, graft function, chronic rejection, acute rejection, mortality, infection, cancer (excluding skin), and cardiovascular disease. Compared with health professionals, patients/caregivers gave higher priority to 6 outcomes (mean difference of 0.5 or more): skin cancer, surgical complications, cognition, blood pressure, depression, and ability to work. We identified 5 themes: capacity to control and inevitability, personal relevance, debilitating repercussions, gaining awareness of risks, and addressing knowledge gaps. Conclusions: Graft complications and severe comorbidities were critically important for both stakeholder groups. These stakeholder-prioritized outcomes will inform the core outcome set to improve the consistency and relevance of trials in kidney transplantation. Abstract : Clinical trials report a variety of clinical, surrogate, or patient-reported outcomes. This article describes the results of novel methods using iterative Delphi Surveys of not only health professionals but patients and caregivers to determine the most important clinical trial outcome endpoints among both groups. Supplemental digital content is available in the text
Evaluation des pratiques cliniques dans la maladie rénale chronique - apport des études observationnelles by Natalia Alencar de Pinho( )

1 edition published in 2019 in French and held by 1 WorldCat member library worldwide

Chronic kidney disease (CKD) affects about 10% of the adult population and is associated with high risk of end-stage kidney disease (ESKD), cardiovascular complications, and premature death. Guidelines recommend a number of measures for the prevention of CKD progression and complications, but these recommendations are often based on low evidence or expert opinion. In this thesis, we used observational data to assess clinical practices in two key areas of CKD: arteriovenous (AV) access for hemodialysis, and hypertension control in moderate to severe CKD. Using data from the French REIN registry of renal replacement therapy for ESKD, we showed that only 56% of the 53,092 adult incident patients on hemodialysis from 2005 through 2013 had an AV access (either fistulae or grafts) created at hemodialysis initiation as recommended, of which 16% were nonfunctional, requiring catheter use associated with high mortality risk. Conversion into functional AV access was associated with better outcome, but less than two out of three patients starting hemodialysis with a catheter experienced this conversion within 3 years after dialysis start. In the CKD-REIN cohort study, among 1658 patients with moderate to severe CKD, we found less hypertension control and higher systolic blood pressure to be associated with higher sodium intake assessed from spot urine, but not with lower potassium intake. Spot urinary sodium/potassium ratio did not appear to add value than sodium alone for patient monitoring. Finally, using data from the International Network of Chronic Kidney Disease cohorts (iNET-CKD), including 17 cohort studies over 4 continents (N=34,602 patients with an estimated glomerular filtration rate < 60 mL/min/1.73 m2), we highlighted a global poor hypertension control in CKD with regards to recommendations, with large variations across countries (from 27 to 61% blood pressure ≥140/90 mm Hg). These variations are partly explained by patients' characteristics, and associated with very different antihypertensive treatment profiles. In conclusion, this thesis points out major gaps between guideline recommendations and CKD management in real life, and provide clues for the prevention of AV access-related complications and better hypertension control
Toward Establishing Core Outcome Domains For Trials in Kidney Transplantation( )

1 edition published in 2017 in English and held by 1 WorldCat member library worldwide

Abstract : Background: Treatment decisions in kidney transplantation requires patients and clinicians to weigh the benefits and harms of a broad range of medical and surgical interventions, but the heterogeneity and lack of patient-relevant outcomes across trials in transplantation makes these trade-offs uncertain, thus, the need for a core outcome set that reflects stakeholder priorities. Methods: We convened 2 international Standardized Outcomes in Nephrology-Kidney Transplantation stakeholder consensus workshops in Boston (17 patients/caregivers; 52 health professionals) and Hong Kong (10 patients/caregivers; 45 health professionals). In facilitated breakout groups, participants discussed the development and implementation of core outcome domains for trials in kidney transplantation. Results: Seven themes were identified. Reinforcing the paramount importance of graft outcomes encompassed the prevailing dread of dialysis, distilling the meaning of graft function, and acknowledging the terrifying and ambiguous terminology of rejection. Reflecting critical trade-offs between graft health and medical comorbidities was fundamental. Contextualizing mortality explained discrepancies in the prioritization of death among stakeholders--inevitability of death (patients), preventing premature death (clinicians), and ensuring safety (regulators). Imperative to capture patient-reported outcomes was driven by making explicit patient priorities, fulfilling regulatory requirements, and addressing life participation. Specificity to transplant ; feasibility and pragmatism (long-term impacts and responsiveness to interventions); and recognizing gradients of severity within outcome domains were raised as considerations. Conclusions: Stakeholders support the inclusion of graft health, mortality, cardiovascular disease, infection, cancer, and patient-reported outcomes (ie, life participation) in a core outcomes set. Addressing ambiguous terminology and feasibility is needed in establishing these core outcome domains for trials in kidney transplantation. Abstract : Standardized Outcomes in Nephrology-Kidney Transplantation (SONG-Tx) convened 2 international consensus workshops in Boston and Hong Kong with patients/caregivers and health professionals to discuss the development and implementation of core outcome domains for trials in kidney transplantation. Supplemental digital content is available in the text
Fp495patient and caregiver priorities for outcomes in peritoneal dialysis: an international nominal group study( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Fp628a core outcome set for trials in haemodialysis established by the standardised outcomes in nephrology - haemodialysis initiative( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Optimizing hypertension management in renal transplantation( )

1 edition published in 2017 in English and held by 1 WorldCat member library worldwide


1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Hétérogénéité des critères de jugement évalués dans les essais randomisés de néphroprotection by Bénédicte Sautenet( )

1 edition published in 2015 in French and held by 1 WorldCat member library worldwide

Outcomes in randomized trials should fulfill high-standard metrological quality (reproducibility, validity, sensitivity to change) as well as clinical relevance. Scientific evidence revealed by clinical trials directly depends on the choice of such outcomes. In addition, the results of these trials and prior trials will be compared on the basis of these outcomes. The choice of similar outcomes for various trials in a same scientific field thus allows for the realization of meta-analyses and finally the optimization of patient care. We aimed to investigate the heterogeneity of outcomes in randomized trials of nephroprotection. First, we compared registered trials in two medical fields, rheumatology and nephroprotection. In rheumatology, an international consensus on outcomes has been established since 1992, whereas no such recommendations exist in the nephrologic field. We therefore compared the description of outcomes in each medical field by means of a score including domain, specific measurement, specific metrics, methods of aggregating data and time frame. These outcomes were then gathered in clusters evaluating the same concept via an international expert' s opinion. Once these clusters are defined, we evaluated the proportion of trials and patients that might be combined for each cluster in a putative meta-analysis. The quality score of outcomes was significantly lower for nephrology than rheumatology trials (odds ratio 4.2 [95% confidence interval 2.39; -7.39], p <0.001). Overall, .20 outcomes were identified in each field: 13 clusters in rheumatology versus 8 in nephrology. In rheumatology, the cluster representing a single outcome (American College of Rheumatology response criteria) allowed for assessing 87.1% of trials and 92.8% of patients likely included in those trials. No such cluster existed in nephrology. These results resulted in lower homogeneity of the outcomes used in randomized trials in nephrology.Our second objective concerned meta-analysis of randomized trials in nephroprotection. We listed the outcomes used in each meta-analysis, then ascertained the proportion of trials associated with each outcome and identified 20 outcomes clustered in 6 subgroups: antiproteinuric impact, kidney efficiency, end-stage kidney disease, composite outcomes aggregating end-stage kidney disease, death and patient-reported outcomes. For each outcome, the proportion of systematic reviews in which the outcome could be meta-analyzed varied from 1.5% to 50.0%. Only 35.5% of outcomes allowed for aggregating more than 75% of randomized trials. These results underline major divergences in the choice of outcomes in systematic reviews and the difficulties in combining trial
moreShow More Titles
fewerShow Fewer Titles
Audience Level
Audience Level
  Kids General Special  
Audience level: 0.93 (from 0.88 for Standardis ... to 0.99 for Evaluation ...)

Alternative Names
Bigot, Bénédicte